Financial Performance - The company's revenue for Q1 2024 was ¥192,086,337.15, representing an increase of 11.93% compared to ¥171,613,712.00 in the same period last year[5] - Net profit attributable to shareholders was ¥42,208,439.85, up 20.42% from ¥35,050,749.84 year-on-year[5] - Basic and diluted earnings per share increased by 20.93% to ¥0.2103 from ¥0.1739[5] - Total operating revenue for Q1 2024 was CNY 192,086,337.15, an increase of 11.5% compared to CNY 171,613,712.00 in Q1 2023[21] - Net profit for Q1 2024 reached CNY 44,455,356.74, representing a 17.5% increase from CNY 37,911,702.93 in Q1 2023[22] - The total comprehensive income for the first quarter of 2024 was CNY 44,455,864.70, an increase from CNY 37,909,230.85 in the previous year, representing a growth of approximately 17.5%[23] Cash Flow and Assets - The net cash flow from operating activities decreased by 30.58% to ¥21,818,792.00 from ¥31,429,846.37 in the previous year[5] - Cash inflow from investment activities totaled CNY 182,548,032.50, significantly higher than CNY 50,814,783.32 in the previous year, marking an increase of about 259.5%[26] - The net cash flow from investment activities was negative CNY 613,217,427.29, compared to negative CNY 498,963,185.24 in the previous year, indicating a worsening of approximately 23%[26] - The cash and cash equivalents at the end of Q1 2024 were approximately 360.77 million yuan, down from 953.31 million yuan at the beginning of the period[16] - Total assets at the end of the reporting period were ¥1,815,048,877.37, a 3.55% increase from ¥1,752,743,944.92 at the end of the previous year[5] - Total liabilities increased to CNY 167,055,467.34 in Q1 2024, up from CNY 149,206,399.59 in Q1 2023, marking an increase of 12%[19] Research and Development - Research and development expenses increased by 30.06% to ¥6,926,956.54, reflecting the company's commitment to innovation[9] - The company's R&D expenses for Q1 2024 amounted to CNY 6,926,956.54, an increase of 30.2% compared to CNY 5,325,996.18 in Q1 2023[22] Sales and Market Expansion - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[5] - In Q1 2024, the company's lens business grew by 20% year-over-year, excluding the negative impact from overseas operations[14] - The revenue from the PMC Ultra Bright series products increased by 77% compared to the same period last year[14] - The sales revenue of the "Easy Control" series products reached 41.08 million yuan, a year-over-year increase of 50%[14] - The company is focusing on enhancing channel strength and distribution efficiency to capture a larger market share[14] - The three star products accounted for 54% of the revenue from regular lenses[14] - The company has established partnerships with well-known domestic lens chain brands, including Baodao Optical and Aier Eye Hospital[14] Other Income and Expenses - The company recorded a 316.04% increase in other income, amounting to ¥4,082,759.42, primarily due to increased government subsidies[9] - The company reported a significant increase in sales expenses, which totaled CNY 35,888,842.97, compared to CNY 33,076,283.58 in the previous year, reflecting a rise of 8.5%[22] Audit and Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 8,073[11] - The report for the first quarter of 2024 was not audited[28]
明月镜片(301101) - 2024 Q1 - 季度财报